Resolvin E1: a novel lipid mediator in the resolution of allergic airway inflammation

Evaluation of: Haworth O, Cernadas M, Yong R, Serhan CN, Levy BD. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A(4) to promote the resolution of allergic airway inflammation. Nat. Immunol. 9(8), 873-879 (2008). Resolvin E1 (RvE1) is an endogenous lipid mediator that was first found in exudates from murine dorsal pouches during the resolution phase upon treatment with aspirin and eicosapentaenoic acid. Intravenous administration of RvE1 during the challenge phase by antigen aerosol clearly dampens the development of allergic airway inflammation. Its administration in the resolution phase also improves airway hyper-reactivity and promotes the resolution of inflammation in the murine model of asthma. RvE1 decreases IL-23, IL-6 and IL-17, which are involved in maintaining inflammation, and increases counter-regulatory IFN-gamma and lipoxin A(4) in the lung. RvE1 and its putative receptor, ChemR23, might open a new avenue in the design of resolution-targeted therapies to control bronchial asthma.